Oric Pharmaceuticals (NASDAQ:ORIC) Now Covered by Analysts at Stifel Nicolaus

Stifel Nicolaus started coverage on shares of Oric Pharmaceuticals (NASDAQ:ORIC) in a research note issued on Friday. The firm set a “buy” rating and a $14.00 price target on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 77.48% from the stock’s current price.

A number of other equities research analysts also recently weighed in on the stock. Citigroup decreased their price target on shares of Oric Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Tuesday, May 5th. Wedbush cut their price objective on Oric Pharmaceuticals from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, April 1st. Cantor Fitzgerald reissued an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Friday, May 22nd. The Goldman Sachs Group raised shares of Oric Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $15.00 price target for the company in a report on Friday, May 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a research report on Tuesday, April 21st. Fourteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Oric Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $18.92.

Oric Pharmaceuticals Stock Up 0.9%

Oric Pharmaceuticals stock traded up $0.07 during mid-day trading on Friday, reaching $7.89. The company had a trading volume of 156,892 shares, compared to its average volume of 1,797,276. The firm has a market cap of $816.57 million, a price-to-earnings ratio of -5.47 and a beta of 1.04. The company has a 50 day moving average of $9.01 and a 200-day moving average of $10.18. Oric Pharmaceuticals has a 52 week low of $7.23 and a 52 week high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03). On average, analysts predict that Oric Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Federation des caisses Desjardins du Quebec raised its holdings in Oric Pharmaceuticals by 100.0% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock worth $33,000 after purchasing an additional 2,000 shares during the period. Assetmark Inc. bought a new stake in shares of Oric Pharmaceuticals in the 3rd quarter valued at $37,000. Caitong International Asset Management Co. Ltd raised its stake in Oric Pharmaceuticals by 184.4% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock worth $37,000 after buying an additional 2,936 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Oric Pharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock worth $39,000 after acquiring an additional 977 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in shares of Oric Pharmaceuticals during the third quarter worth about $60,000. Institutional investors and hedge funds own 95.05% of the company’s stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.